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Summary We present the case of a 48-year-old man with unstable angina who underwent
drug-eluting stent (DES) implantation for the left circumﬂex artery (LCx). Red thrombi within
the stent were clearly found by coronary angioscopy. Dual antiplatelet therapy was orally given
before the stenting. Twenty-two months after the procedure, the patient visited because of
severe chest pain. The patient had stopped taking all prescriptions including antiplatelet drugs
for the previous 18 months. The occurrence of late stent thrombosis (LST) derived from pre-
viously implanted DES in the LCx was strongly suspected. Unexpectedly, the left coronary
angiograms showed neither in-stent restenosis nor thrombotic occlusion. Angioscopic images
for the DES segment showed that there were no uncovered stent struts without neointimal
coverage. Notably, red thrombi identiﬁed immediately after stenting by angioscopy had com-
pletely disappeared. Mural red thrombi at the ﬁrst observation completely disappeared despite
premature cessation of dual antiplatelet therapy. Early neointimal coverage may occasionally
occur even under the condition of acute coronary syndrome. The leading cause of LST was
not only the cessation of dual-antiplatelet therapy and multiple factors contribute to LST of
DES. Relatively early and adequate neointimal stent coverage may reduce the risk of thrombus
formation including LST even th
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Introduction
In recent years, late stent thrombosis (LST) after drug-
eluting stent (DES) implantation has become a major clinical
concern. A long-term follow-up study revealed that LST
occurs at a constant rate of 0.4—0.6% per year for up to four
years after DES implantation [1]. Up to now, optimal dura-
tion of dual antiplatelet treatment after DES implantation
for prevention of LST is unclear. However, premature discon-
tinuation of antiplatelet therapy is an established predictor
of subacute thrombosis and LST [2]. A previous serial angio-
scopic study demonstrated new thrombus formation in the
DES despite continuous administration of dual antiplatelet
therapy (DAPT) [3]. The inﬂuence of premature discontinua-
tion of antiplatelet therapy on appearance or disappearance
of thrombus in DES is uncertain.
Case report
A 48-year-old man with unstable angina underwent coro-
nary stenting under guidance with intravascular ultrasound
(IVUS) for severe stenosis in the left circumﬂex artery
(LCx). He was a current smoker and diagnosed as hav-
ing impaired glucose tolerance (IGT; glycated hemoglobin
A1c 5.2%), hypertension, dyslipidemia, and renal insufﬁ-
ciency (creatinine 1.16mg/dl). After balloon angioplasty
(Quantum MaverickTM, 3.25/15mm; Boston Scientiﬁc, Nat-
ick, MA, USA), a sirolimus-eluting stent (Cypher stentTM,
3.5/18mm; Cordis, Bridgewater, NJ, USA) was deployed at
a pressure of 20 atm (Fig. 1B). Red thrombi within the stent
were clearly found by coronary angioscopy (Fig. 1C and
D). DAPT, aspirin 200mg, and ticlopidine 200mg/day, were
orally given before the stenting. Atorvastatin (20mg/day),
nicorandil (15mg/day), enalapril (10mg/day), and azelni-
dipine (8mg/day) were also given for control of coronary
risk factors and his low-density lipoprotein cholesterol level
was 102mg/dl before discharge. Twenty-two months after
the procedure, the patient visited our hospital because of
severe chest pain. The patient had stopped taking all pre-
scriptions including antiplatelet drugs by his own judgment
for the previous 18 months. The occurrence of LST derived
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Figure 1 (A) Coronary angiography (CAG) revealed a mild stenosis
stenosis in the distal of left circumﬂex artery. The vessel was success
blue arrow). (C and D) Coronary angioscopy showed mural reddish the discontinuation of antiplatelet therapy e5
rom previously implanted DES in the LCx was strongly
uspected and we performed emergent coronary angiog-
aphy (CAG). Unexpectedly, the left coronary angiograms
howed neither in-stent restenosis nor thrombotic occlusion
Fig. 2B) and angiographic late loss in the stent segment
as 0.2mm. Alternatively, there was an atherosclerotic
esion progressing mild to severe stenosis in the right coro-
ary artery (Figs. 1A and 2A). Angioscopic images for the
ES segment showed that there were no uncovered stent
truts without neointimal coverage. Notably, red thrombi
dentiﬁed immediately after stenting by angioscopy com-
letely disappeared (Fig. 2C and D). The 3rd CAG was
lanned to assess whether the thin-layer structures identi-
ed by macroscopic diagnosis had an adequate endothelial
unction, and endothelium-dependent coronary vasomotion
as estimated by intracoronary infusion of incremental
oses of acetylcholine (ACh), 0.3g/min, 3g/min, and
0g/min, into the ostium of left coronary artery. Abnor-
al vasoconstriction to Ach was not induced in this case
Fig. 3), it was therefore proven that the neointima
ad a good endothelial function with anti-thrombotic
ffect.
iscussion
ong-term follow-up observations focusing on neointimal
overage after DES implantation showed that uncovered
truts and subclinical thrombus formation remained occa-
ionally [3]. In the current case, angioscopy could not
dentify any uncovered struts and the majority of struts
ere fully covered by thin neointima. No thrombi were rec-
gnized at the second observation by angioscopy. In other
ords, mural red thrombi at the ﬁrst observation completely
isappeared despite immature cessation of DAPT.
According to a recent analysis of optical coherence
omography, the frequency of uncovered struts was cor-
elated with abnormal vasoconstriction by intracoronary
Ch provocation after zotarolimus-eluting stent implanta-
ion [4]. In a previous report with angioscopy, 13% of SESs
ad complete coverage that means stent struts were visi-
le but not translucent or struts were not visible (grade 2
in the distal of right coronary artery. (B) CAG revealed a severe
fully treated with a sirolimus-eluting stent (Cypher 3.5/18mm,
rombi with yellow plaque.
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Figure 2 (A) The second coronary angiogram (CAG) revealed a progressive stenosis in the distal of the right coronary artery.
(B) The second CAG showed no signiﬁcant in-stent stenosis and no thrombotic occlusion in the left circumﬂex artery. (C and D)
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Foronary angioscopy showed most of the stent struts were visibl
eointima. There was no complete exposure without neointima
r 3, respectively) following 3—6 months of their implan-
ation [5]. In the present case, neointimal coverage on all
truts was regarded as grade 2 or 3. Moreover, the thin-
ayer structures identiﬁed by macroscopic diagnosis with
ngioscopy have an adequate endothelial function including
nti-thrombotic effect. Probably, the neointima sufﬁciently
ight have covered over the struts in relatively early phase
ecause LST did not occur in the present case despite imma-
ure DAPT discontinuation.
It is meaningful to consider the mechanism of the unex-
ected phenomena without stent thrombosis. First, the
eployed stent had large diameter with satisfactory attach-
ent to the vessel wall, so-called good apposed stent on
VUS ﬁndings. Adequate stent dilatation to the vessel con-
ributes to the complete neointimal coverage by angioscopy
fter SES implantation [6].
Second, stent length was not so long because the culprit
esion was discrete. Longer stenting is one of the predictors
f stent thrombus formation.
Third, the pre-existing yellow plaque and mural thrombi
ight be associated with decreased neointimal cov-
rage of SES [7]. Otherwise, it was recently reported
hat acute coronary syndrome might promote neointimal
m
e
t
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igure 3 (A—C) There were no vasoconstrictive responses to intraer a thin neointima and some struts were invisible by the thick
re were also no massive protruding and mural thrombi.
overage after SES implantation [8]. Early neointimal
overage could occasionally occur even under the condition
f acute coronary syndrome including unstable angina as in
his case.
Diabetes mellitus (DM) is an independent predic-
or of early ST which occurs within 30 days after
tent deployment. By contrast, neointimal coverage
nd its thickness are greater in DM than in non-DM
fter SES implantation [9]. DM and IGT show similar
haracteristics of vessel pathophysiology, therefore IGT
ight contribute to early neointimal coverage in this
ase.
The mechanisms of stent thrombosis after DES implan-
ation are multi-factorial and include the patient, lesion,
nd procedural factors, as well as the drug compliance or
he reactivity to antiplatelet therapy. Similarly, the leading
ause of LST was not only the cessation of DAPT and multi-
le factors contribute to LST of DES. As this case suggested,
elatively early and adequate neointimal stent coverage
ay reduce the risk of thrombus formation including LST
ven though anti-platelet therapy was discontinued imma-
urely. LST of ﬁrst-generation DES constantly occurs at an
nnual rate of 0.4—0.6%, we should therefore be aware of
coronary acetylcholine (Ach) infusion. GTN, glyceryl trinitrate.
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the possibility of LST after discontinuation of anti-platelet
treatment. Nevertheless, the present case may support DES
safety in speciﬁc patients regardless of immature cessation
of DAPT.
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